PT - JOURNAL ARTICLE AU - Bruel, Timothée AU - Stéfic, Karl AU - Nguyen, Yann AU - Toniutti, Donatella AU - Staropoli, Isabelle AU - Porrot, Françoise AU - Guivel-Benhassine, Florence AU - Bolland, William-Henry AU - Planas, Delphine AU - Hadjadj, Jérôme AU - Handala, Lynda AU - Planchais, Cyril AU - Prot, Matthieu AU - Simon-Lorière, Etienne AU - André, Emmanuel AU - Baele, Guy AU - Cuypers, Lize AU - Mouthon, Luc AU - Mouquet, Hugo AU - Buchrieser, Julian AU - Sève, Aymeric AU - Prazuck, Thierry AU - Maes, Piet AU - Terrier, Benjamin AU - Hocqueloux, Laurent AU - Schwartz, Olivier TI - Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies AID - 10.1101/2022.08.12.22278699 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.12.22278699 4099 - http://medrxiv.org/content/early/2022/08/13/2022.08.12.22278699.short 4100 - http://medrxiv.org/content/early/2022/08/13/2022.08.12.22278699.full AB - The emergence of novel Omicron lineages, such as BA.5, may impact the therapeutic efficacy of anti-SARS-CoV-2 neutralizing monoclonal antibodies (mAbs). Here, we evaluated the neutralization and ADCC activity of 6 therapeutic mAbs against Delta, BA.2, BA.4 and BA.5 isolates. The Omicron sub-variants escaped most of the antibodies but remained sensitive to Bebtelovimab and Cilgavimab. Consistent with their shared spike sequence, BA.4 and BA.5 displayed identical neutralization profiles. Sotrovimab was the most efficient at eliciting ADCC. We also analyzed 121 sera from 40 immunocompromised individuals up to 6 months after infusion of 1200 mg of Ronapreve (Imdevimab + Casirivimab), and 300 or 600 mg of Evusheld (Cilgavimab + Tixagevimab). Sera from Ronapreve-treated individuals did not neutralize Omicron subvariants. Evusheld-treated individuals neutralized BA.2 and BA.5, but titers were reduced by 41- and 130-fold, respectively, compared to Delta. A longitudinal evaluation of sera from Evusheld-treated patients revealed a slow decay of mAb levels and neutralization. The decline was more rapid against BA.5. Our data shed light on the antiviral activities of therapeutic mAbs and the duration of effectiveness of Evusheld pre-exposure prophylaxis.Competing Interest StatementT.B., C.P., H.M. and O.S. have a pending patent application for an anti-RBD mAb not used in this study (PCT/FR2021/070522). All other authors declare no conflicts of interest.Funding StatementWork in the O.S. lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito and IDISCOVR. Work in the UPBI facility is funded by grant ANR-10-INSB-04-01 and the Region Ile-de-France program DIM1Health. D.P. is supported by the Vaccine Research Institute. P.M. acknowledges support of a COVID-19 research grant from Fonds Wetenschappelijk Onderzoek Research Foundation Flanders (grant G0H4420N) and Internal Funds KU Leuven (grant 3M170314). E.S.L. acknowledges funding from the INCEPTION program (Investissements d Avenir grant ANR-16-CONV-0005). The funders of this study had no role in study design, data collection, analysis and interpretation or writing of the article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Individuals under Evusheld PreP were recruited in the French cities of Orleans and Paris (CHR d Orleans and Hopital Cochin). The Neutralizing Power of Anti-SARS-CoV-2 Serum Antibodies (PNAS) cohort is an ongoing prospective, monocentric, longitudinal, observational cohort clinical study aiming to describe the kinetics of neutralizing antibodies after SARS-CoV-2 infection or vaccination (ClinicalTrials.gov identifier: NCT05315583). The cohort takes place in Orleans, France and enrolled immunocompromised individuals receiving Evusheld PreP. This study was approved by the Est II (Besancon) ethical committee. At enrollment, written informed consent was collected, and participants completed a questionnaire that covered sociodemographic characteristics, clinical information and data related to anti-SARS-CoV-2 vaccination. Blood sampling was performed on the day of Evusheld infusion and after 3 days, 15 days and then every months. The Cochin cohort is a prospective, monocentric, longitudinal, observational clinical study (NCT04870411) enrolling immunocompromised individuals with rheumatic diseases, aiming at describing immunological responses to COVID- 19 vaccine in patients with autoimmune and inflammatory diseases treated with immunosuppressants and or biologics. Ethics approval was obtained from the Comite de Protection des Personnes Nord-Ouest II. Leftover sera from usual care were used from these individuals in the setting of the local biological samples collection (RAPIDEM). A written informed consent was collected for all participants. None of the study participants received compensation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data supporting the findings of this study are available within the article or from the corresponding authors upon reasonable request without any restrictions.